Free Trial
NASDAQ:BOLT

Bolt Biotherapeutics (BOLT) Stock Price, News & Analysis

Bolt Biotherapeutics logo
$0.66
+0.02 (+3.13%)
(As of 11/1/2024 ET)

About Bolt Biotherapeutics Stock (NASDAQ:BOLT)

Key Stats

Today's Range
$0.64
$0.66
50-Day Range
$0.58
$0.69
52-Week Range
$0.55
$1.56
Volume
24,440 shs
Average Volume
168,994 shs
Market Capitalization
$25.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.50
Consensus Rating
Hold

Company Overview

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Bolt Biotherapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
54th Percentile Overall Score

BOLT MarketRank™: 

Bolt Biotherapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 356th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bolt Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Bolt Biotherapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Bolt Biotherapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Bolt Biotherapeutics are expected to grow in the coming year, from ($1.52) to ($0.99) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bolt Biotherapeutics is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bolt Biotherapeutics is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Bolt Biotherapeutics has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Bolt Biotherapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.46% of the float of Bolt Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Bolt Biotherapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bolt Biotherapeutics has recently increased by 0.34%, indicating that investor sentiment is decreasing.
  • Percentage of Shares Shorted

    0.46% of the float of Bolt Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Bolt Biotherapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bolt Biotherapeutics has recently increased by 0.34%, indicating that investor sentiment is decreasing.
  • Search Interest

    1 people have searched for BOLT on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bolt Biotherapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    30.90% of the stock of Bolt Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    86.70% of the stock of Bolt Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Bolt Biotherapeutics' insider trading history.
Receive BOLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

BOLT Stock News Headlines

Ex WH Advisor Who Predicted Biden Leaving Race Makes Startling New Prediction
Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.
See More Headlines

BOLT Stock Analysis - Frequently Asked Questions

Bolt Biotherapeutics' stock was trading at $1.12 at the beginning of 2024. Since then, BOLT shares have decreased by 41.2% and is now trading at $0.6585.
View the best growth stocks for 2024 here
.

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) announced its earnings results on Tuesday, August, 13th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.48) by $0.08. The company had revenue of $1.28 million for the quarter, compared to analyst estimates of $1.19 million. Bolt Biotherapeutics had a negative net margin of 592.57% and a negative trailing twelve-month return on equity of 61.40%.

Bolt Biotherapeutics (BOLT) raised $150 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities served as the underwriters for the IPO.

Shares of BOLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bolt Biotherapeutics investors own include Athenex (ATNX), NIO (NIO), Plug Power (PLUG), Alibaba Group (BABA), Moderna (MRNA), NVIDIA (NVDA) and XPeng (XPEV).

Company Calendar

Last Earnings
8/13/2024
Today
11/02/2024
Next Earnings (Estimated)
11/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:BOLT
CUSIP
09769810
Fax
N/A
Employees
100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.50
High Stock Price Target
$8.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+431.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$-69,200,000.00
Net Margins
-592.57%
Pretax Margin
-592.57%

Debt

Sales & Book Value

Annual Sales
$11.17 million
Book Value
$2.97 per share

Miscellaneous

Free Float
26,441,000
Market Cap
$25.20 million
Optionable
Not Optionable
Beta
0.93

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

This page (NASDAQ:BOLT) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners